Bausch + Lomb Co. (NYSE:BLCO) Receives Average Rating of "Moderate Buy" from Analysts

Bausch + Lomb Co. (NYSE:BLCO - Get Free Report) has been assigned an average rating of "Moderate Buy" from the twelve brokerages that are presently covering the firm, Marketbeat.com reports. Five investment analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1 year price target among analysts that have covered the stock in the last year is $20.91.

BLCO has been the subject of a number of recent analyst reports. Wells Fargo & Company boosted their target price on shares of Bausch + Lomb from $23.00 to $26.00 and gave the company an "overweight" rating in a research note on Thursday, October 31st. Royal Bank of Canada lifted their price target on shares of Bausch + Lomb from $20.00 to $23.00 and gave the company an "outperform" rating in a research note on Tuesday, October 22nd. Citigroup increased their price objective on Bausch + Lomb from $20.00 to $24.00 and gave the stock a "buy" rating in a research note on Thursday, October 31st. Deutsche Bank Aktiengesellschaft upped their target price on Bausch + Lomb from $14.00 to $18.00 and gave the stock a "hold" rating in a report on Thursday, August 1st. Finally, Evercore ISI upgraded Bausch + Lomb from an "in-line" rating to an "outperform" rating and raised their price target for the company from $19.00 to $25.00 in a research note on Tuesday, October 15th.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. Gabelli Funds LLC raised its stake in Bausch + Lomb by 3.3% in the first quarter. Gabelli Funds LLC now owns 312,000 shares of the company's stock valued at $5,398,000 after buying an additional 10,000 shares during the last quarter. Whitebox Advisors LLC boosted its stake in Bausch + Lomb by 29.3% in the 1st quarter. Whitebox Advisors LLC now owns 1,206,303 shares of the company's stock worth $20,869,000 after purchasing an additional 273,484 shares in the last quarter. Invenomic Capital Management LP purchased a new stake in Bausch + Lomb during the 1st quarter worth approximately $6,817,000. Rokos Capital Management LLP acquired a new position in Bausch + Lomb during the 1st quarter valued at approximately $5,602,000. Finally, Renaissance Capital LLC raised its holdings in shares of Bausch + Lomb by 57.2% in the second quarter. Renaissance Capital LLC now owns 36,286 shares of the company's stock worth $527,000 after buying an additional 13,210 shares during the last quarter. Institutional investors own 11.07% of the company's stock.

Bausch + Lomb Trading Up 0.6 %

Bausch + Lomb stock traded up $0.11 during midday trading on Friday, reaching $19.68. The stock had a trading volume of 465,864 shares, compared to its average volume of 565,835. The company has a quick ratio of 0.95, a current ratio of 1.57 and a debt-to-equity ratio of 0.69. The firm has a market cap of $6.93 billion, a price-to-earnings ratio of -18.74, a price-to-earnings-growth ratio of 1.93 and a beta of 0.46. Bausch + Lomb has a 52-week low of $13.16 and a 52-week high of $21.69. The company has a fifty day moving average of $19.35 and a 200 day moving average of $16.83.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of $0.16 by $0.01. Bausch + Lomb had a positive return on equity of 3.17% and a negative net margin of 7.86%. The firm had revenue of $1.20 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same period in the prior year, the business posted $0.22 earnings per share. The company's revenue for the quarter was up 18.8% on a year-over-year basis. On average, analysts anticipate that Bausch + Lomb will post 0.59 earnings per share for the current fiscal year.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.